Results 21 to 30 of about 103,888 (259)
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis, 2020 Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its appropriate treatment.
X. L. Zheng +13 more
semanticscholar +1 more source
How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]
, 2014 Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core +1 more source
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis, 2020 Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly.
X. L. Zheng +13 more
semanticscholar +1 more source
Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. [PDF]
, 2015 BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease in which anti-ADAMTS13 autoantibodies cause severe enzyme deficiency.
Crawley, JT +3 more
core +2 more sources
Idiopathic Thrombocytopenic Purpura
Definitions, 2020 B-cell disorders include a large group of malignant and nonmalignant diseases with tremendous variation in incidence, natural history, treatment, and prognosis.
Amy Goodrich
semanticscholar +1 more source
A case of immune thrombocytopenic purpura presenting with intracranial hemorrhage
Journal of Acute Disease, 2013 Immune thrombocytopenic purpura is an acute, generally considered a self-limiting benign disorder with a 60%-80% change of spontaneous recovery occurring usually within a few months after onset.
Sinan Akbayram +5 more
doaj +1 more source
Discussion required for correct interpretation [PDF]
, 2006 Thank you for the opportunity to comment on the editorial by Romero and colleagues [1], which raises a number of important and interesting questions.
Aguan +10 more
core +3 more sources
Journal of Thrombosis and Haemostasis, 2020 Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody ...
L. Völker +7 more
semanticscholar +1 more source
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
New England Journal of Medicine, 2019 BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully +12 more
semanticscholar +1 more source
Journal of Thrombosis and Haemostasis, 2020 Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its management.
X. L. Zheng +13 more
semanticscholar +1 more source